| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Anti-Dinutuximab Ab |
| species reactivity | Universal |
| applications | Double antigen, Sandwich ELISA |
| assay type | direct & quantitative |
| available size | 96 tests |
| sensitivity | 0.938ng/ml |
| range | 1.563-100ng/ml |
Anti-Dinutuximab antibody ELISA Kit 60207
$570.00
Summary
- ELISA kit for research use (RUO)
- Reactivity: Anti-Dinutuximab Ab
- Suitable for: ELISA
- Time:3 hours
- Sample types:Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples
Anti-Dinutuximab antibody ELISA Kit
| kit | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay type Bridging ELISA | ||||||||||||||||||||||
| Research area biologic | ||||||||||||||||||||||
| Sample type Serum, Plasma, Cell Culture Supernatant, Other liquid samples | ||||||||||||||||||||||
Components
| ||||||||||||||||||||||
| Storage Store at 2-8°C. |
| target relevance |
|---|
| anti-Dinutuximab antibody Anti-drug antibodies (ADAs) generated in subjects following administration of Dinutuximab. |
| Protein names Disialoganglioside GD2 |
| Alternative names GD2, Ganglioside GD2, Disialoganglioside GD2, CDw60 |
| Function GD2 participates in cell-cell interactions, signal transduction, cell adhesion, migration, and modulation of cellular growth and differentiation. |
| Subcellular location Cell membrane; enriched within plasma membrane lipid rafts. |
| Involvement in disease GD2 is an important tumor-associated antigen and therapeutic target in neuroblastoma and other malignancies. |
| Description GD2 is a disialoganglioside cell-surface glycolipid belonging to the ganglioside family. It is highly expressed on neuroblastoma, melanoma, osteosarcoma, and other tumors of neuroectodermal origin, while exhibiting limited expression in normal tissues, primarily peripheral nerves and central nervous system tissues. |
| Chemical description Ganglioside Glycosphingolipid Disialoganglioside |
| Related entities relationship: related_to; entity: GM2 ganglioside relationship: related_to; entity: GD3 ganglioside relationship: related_to; entity: GT1b ganglioside relationship: target_of; entity: Dinutuximab relationship: target_of; entity: Naxitamab |
| Keywords Ganglioside, Glycolipid, Neuroblastoma, Melanoma, Cancer immunotherapy |
| Structure GD2 is a disialoganglioside glycosphingolipid containing a ceramide lipid anchor and a complex carbohydrate chain with two sialic acid residues. |
| Function GD2 participates in membrane organization, cell adhesion, signal transduction, migration, and cellular interactions. |
| Expression GD2 is highly expressed on neuroblastoma and other neuroectodermal tumors, with relatively restricted expression in normal tissues. |
| Clinical relevance GD2 is an established therapeutic target for neuroblastoma. FDA-approved anti-GD2 antibodies include dinutuximab and naxitamab. |
| Research relevance GD2 is widely used as a tumor biomarker and immunotherapy target in cancer research, antibody development, CAR-T cell engineering, and diagnostic assays. |
Data
Standard Curve
X axis: log |
Y axis: linear
| Standard | STD [ng/mL] | OD1 | OD2 | Average OD | Corrected OD |
|---|---|---|---|---|---|
| Blank #8 | 0 | 0.09 | 0.09 | 0.09 | 0 |
| Standard #7 | 1.56 | 0.15 | 0.15 | 0.15 | 0.06 |
| Standard #6 | 3.13 | 0.31 | 0.32 | 0.32 | 0.23 |
| Standard #5 | 6.25 | 0.42 | 0.43 | 0.43 | 0.34 |
| Standard #4 | 12.5 | 0.77 | 0.79 | 0.78 | 0.7 |
| Standard #3 | 25 | 1.25 | 1.29 | 1.27 | 1.18 |
| Standard #2 | 50 | 1.87 | 1.92 | 1.9 | 1.81 |
| Standard #1 | 100 | 2.45 | 2.52 | 2.48 | 2.4 |
Precision
| Sample | n | Mean | Standard Deviation | CV (%) |
|---|---|---|---|---|
| Intra Sample 1 | 20 | 3.16 | 0.18 | 5.72 |
| Intra Sample 2 | 20 | 12.3 | 0.58 | 4.69 |
| Intra Sample 3 | 20 | 48.28 | 2.53 | 5.23 |
| Inter Sample 1 | 20 | 3.05 | 0.15 | 4.88 |
| Inter Sample 2 | 20 | 12.72 | 0.63 | 4.98 |
| Inter Sample 3 | 20 | 49.59 | 2.4 | 4.83 |
Recovery
| Matrix | Recovery Range (%) | Average (%) |
|---|---|---|
| Serum(n=5) | 92-105 | 96 |
| EDTA Plasma(n=5) | 87-103 | 94 |
| HeparinPlasma(n=5) | 90-103 | 95 |
Stability
| 37°C 1 Month (%) | 2–8°C 6 Months (%) | 2–8°C 12 Months (%) |
|---|---|---|
| 80 | 95-100 | 85-98 |
Linearity
| Sample | 1:2 Dilution (%) | 1:4 Dilution (%) | 1:8 Dilution (%) |
|---|---|---|---|
| Serum(n=5) | 99-104% | 95-100% | 91-100% |
| EDTAPlasma(n=5) | 85-103% | 84-97% | 84-99% |
| Heparin Plasma(n=5) | 95-104% | 83-99% | 88-100% |
FAQ & Publications
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Protocols
| Relevant to this product |
|---|
| View Protocol | View PDF |
Documents
| # | ||
|---|---|---|
| Please enter your product and batch number here. | ||
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.